Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations

Nature Genetics

Volumn 7, Issue 1, 1994, Pages 91-97

  Bardeesy, Nabeel ^a   Falkoff, David ^a   Petruzzi, Mary Jane ^b   Nowak, Norma ^b   Zabel, Bernhard ^c   Adam, Mohammed ^d   Aguiar, Maria C ^e   Grundy, Paul ^f   Shows, Tom ^b   Pelletier, Jerry ^a,g  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY AT BUFFALO   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^e Izaak Walton Killam Hospital for Children   (Canada)

^f CROSS CANCER INSTITUTE   (Canada)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER GENETICS; CANCER RISK; CHROMOSOME 17P; CHROMOSOME ANALYSIS; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MARKER GENE; NEPHROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0028168146     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng0594-91     Document Type: Article

References (39)

1. Matsunaga, E. Genetics of Wilms' tumour. Hum Genet. 57, 231-246 (1981).
2. Miller, R.W., Fraumeni, J.F., Jr., & Manning, M.D. Association of Wilms' tumour with aniridia, hemihypertrophy and other congenital malformations. New Eng1. J. Med. 270, 922-927 (1964).
3. Denys, P., Malvaux, P., van den Berghe, H., Tanghe, W. & Proesmans, W. Association d'un syndrome anatomo-pathologique de pseudohérmaphrodisme mascuiin, d'une tumeur de Wilms, d'une néphropathie parenchymateuse et d'un mosalcisme XX/XY. Arch. Fran. Ped. 24, 729-739 (1967).
4. Drash, A., Sherman, F., Hartmann, W.H. & Blizzard, R.M. A syndrome of pseudohermaphrodltism, Wilms' tumour, hypertension, and degenerative renal disease. J. Ped. 76, 585-593 (1970).
5. Wiedemann, H.R. Complexe malformatif familial avec hernie ombilicale et macroglossie-Un syndrome nouveau? J. Génét. Hum. 13, 223-232 (1964).
6. Riccardi, V.M., Sujansky, E., Smith, A.C. & Francke, U. Chromosomal imbalance in the aniridia/Wilms' tumour association: 11 p interstitial deletion. Pediatrics 61, 604-610 (1978).
7. Call, K.M. et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumour locus. Cell 60, 509-520 (1990).
8. Gessler, M. et al. Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. Nature 343, 774-778 (1990).
9. Pelletier, J. et al. Germline mutations in the Wilms' tumour suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67, 437-447 (1991).
10. Bruening, W. et al. Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development. Nature Genet. 1, 144-148 (1992).
11. Pelletier, J. et al. Genetic evidence implicating the Wilms' tumour gene (WT1) in genitourinary development. Nature 353, 431-434 (1991).
12. Pelletier, J., Munroe, D. & Housman, D. in Genome Analysis Vol 3: Genes & Phenotypes (eds Davies, K.E. & Tilghman, S.M.) 135-169 (Cold Spring Harbor Laboratory Press, New York, 1991).
13. Maw, M.A. et al. A third Wilms' tumour locus on chromosome 16q. Cancer Res. 52, 3094-3098 (1992).
14. Knudson, A.G. Mutation and cancer: a statistical study. Proc. natn. Acad. Sci. U.S.A. 68, 820-823 (1971).
15. Levine, A.J., Momand, J. & Finlay, C.A. The p53 tumour suppressor gene.Nature 351, 453-456 (1991).
16. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 Mutations in human cancers. Science 253, 49-53 (1991).
17. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature362, 847-849 (1993).
18. Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
19. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993).
20. D'Angio, G.J. et al. Treatment of Wilms' tumour. Results from the third National Wilms' tumour study. Cancer 64, 349-360 (1989).
21. Murakami, Y., Hayashi, K. & Sekiya, T. Detection of aberrations of the p53 alleles and the gene transcript in human tumour cell lines by single-strand conformation polymorphism analysis. Cancer Res. 51, 3356-3361 (1991).
22. Zuppan, C.W., Beckwith, J.B. & Luckey, D.W. Anaplasia in unilateral Wilms' tumour: a report from the national Wilms' tumour study pathology center. Hum. Path. 19, 1199-1209 (1988).
23. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L. & Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83 (1992).
24. Ladanyi, M. et al. MDM2 gene amplification in metastatic osteosarcoma.Cancer Res. 53, 16-18 (1993).
25. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E.E. & Collins, V.P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53, 2736-2739 (1993).
26. Dittmer, D. et al. Gain of function mutations in p53. Nature Genet. 4, 42-45 (1993).
27. de Fromentel, C.C. & Soussi, T. TP53 tumour suppressor gene: a model for investigating human mutagenesis. Genes. Chrom. Cancer 4, 1-15 (1992).
28. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
29. Srivastava, S., Zhiquiang, Z., Pirollo, K., Blattner, W. & Chang, E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747-749 (1990).
30. Hartley, A.L. et al. Wilms' tumour in the Li-Fraumeni cancer family syndrome. Cancer Genet. Cytogenet. 67, 133-135 (1993).
31. Ladd, W.E. Embryoma of the kidney (Wilms tumour). Ann. Surg. 108, 885-902 (1938).
32. Gross, R.E. & Neuhauser, E.B.D. Treatment of mixed tumours of kidney in childhood. Pediatrics 6, 843-852 (1950).
33. Lemoine, N.R., Hughes, C.M. & Cowell, J.K. Aberrant expression of the tumour suppressor gene p53 is very frequent in Wilms' tumours. J. Path.168, 237-242 (1992).
34. Lowe, S.W. & Ruley, H.E. Stabilization of the p53 tumour suppressor is induced by adenovirus E1A and accompanies apoptosis. Genes Dev. 7, 535-545 (1993).
35. Maheswaran, S. et al. Physical and functional interaction between WT1 and p53 proteins. Proc. natn. Acad. Sci. U.S.A. 90, 5100-5104 (1993).
36. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
37. Kreideberg, J.A. et al. WT-1 is required for early kidney development.Cell 74, 679-691 (1993).
38. Jackson, D.P., Hayden, J.D. & Quirke, P. in PCR-A Practical Approach(eds., McPherson, M.J., Quirke, P. & Taylor, G.R.) 29-50 (Oxford University Press, Oxford, 1992).
39. Sanger, A.F., Nicklen, S. & Coulson, A.R. DNA sequencing with chain-terminating inhibitors. Proc. natn. Acad. Sci. U.S.A. 74, 5463-5467 (1977).